hematological-malignancies

Documents about hematological-malignancies

• M-2018-334 in Hematological Malignancies#867770ClinicalTrials.gov
• A Clinical Study of HMPL-506 in Patients With Hematological Malignancies#1307219ClinicalTrials.gov
• Biodistribution, Dosimetry, and Safety of 68Ga-EV203 in Hematological Malignancies#1293278ClinicalTrials.gov
• Exploratory Study on the Treatment of Recurrent and Refractory Hematological Malignancies With WGb-0302 Injection#303716ClinicalTrials.gov
• Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects#865488ClinicalTrials.gov
• Study of AZD9829 in CD123+ Hematological Malignancies#1211853ClinicalTrials.gov
• Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies#1371744ClinicalTrials.gov
• Exercise During Chemotherapy for Patients With Hematological Malignancies#876014ClinicalTrials.gov
• A Study of TQB3820 in Patients With Hematological Malignancies#812569ClinicalTrials.gov
• PRevention Of BLeeding in hEmatological Malignancies With Antifibrinolytic (Epsilon Aminocaproic Acid)#880495ClinicalTrials.gov
• Thymosin Alfa 1 in Recipients of Allogeneic Hematopoietic Transplantation for Hematological Malignancies#1484803ClinicalTrials.gov
• Study of T Specific Immune Response Against Delta-CD20 Peptide in Hematological Malignancies B#181755ClinicalTrials.gov
• Sequential Radiotherapy With CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies With Extramedullary Lesions#454029ClinicalTrials.gov
• A Phase I Trial of QLS2313 Injection in Relapsed/Refractory Hematological Malignancies#916791ClinicalTrials.gov
• Allogeneic Immunotherapy of Hematological Malignancies Using Regulatory T-cell Selective Depletion#417535ClinicalTrials.gov
• Tissue Microarray of Hematological Malignancies#911988ClinicalTrials.gov
• Distraction With Virtual Reality From Pain and Anxiety for Patients With Hematological Malignancies#849050ClinicalTrials.gov
• Allogeneic Immunotherapy for Hematological Malignancies by Selective Depletion of Regulatory T Cells#471454ClinicalTrials.gov
• Drug Response Profiling (DRP) Registry Zurich for Hematological Malignancies#886860ClinicalTrials.gov
• Pretransplant Evaluation by Supportive Care Team for Patients Undergoing HCT for Hematological Malignancies#1074547ClinicalTrials.gov
• A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004)#1030296ClinicalTrials.gov
• A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies#1047390ClinicalTrials.gov
• Reduced Intensity Haploidentical Transplant for Hematological Malignancies#1164837ClinicalTrials.gov
• Factors associated with treatment resumption and long-term outcomes after ICU discharge in patients with hematological malignancies#1000638HAL (France)
• 18F-Pentixafor PET in Hematologic Malignancies#1075589ClinicalTrials.gov
• Telomere and telomerase in hematological disorders Focusing on bone marrow failure syndromes and hematological malignancies#930385Acta Interna: The Journal of Internal Medicine
• A Study of TQB3473 Tablets in Subjects With Relapsed or Refractory Hematological Malignancies#1396549ClinicalTrials.gov
• A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies#1440230ClinicalTrials.gov
• Stem Cell Transplantation for Hematological Malignancies#1476372ClinicalTrials.gov
• Dual PD-1 and JAK2 Inhibition in Hematological Malignancies#828841ClinicalTrials.gov
• Trial of Pimasertib in Hematological Malignancies#877176ClinicalTrials.gov
• Allogeneic HCT With HLA-matched Donors : a Phase II Randomized Study Comparing 2 Nonmyeloablative Conditionings#1182781ClinicalTrials.gov
• LMP1 CAR-T for Patients With LMP1 Positive Infectious Diseases and Hematological Malignancies#1279338ClinicalTrials.gov
• Febuxostat for Tumor Lysis Syndrome Prevention in Hematological Malignancies of Paediatric Patients and Adults#1294307ClinicalTrials.gov
• Detection of Bloodstream Pathogens in Hematological Malignancies#143588ClinicalTrials.gov
• Digital intrinsic capacity assessment of older patients with hematological malignancies: The ONCO-ICOPE cohort#126863HAL (France)
• Antibacterial Prophylaxis vs no Prophylaxis for Hematological Malignancies Patients Before Allo-HSCT#872292ClinicalTrials.gov
• Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe Myelofibrosis#1419834ClinicalTrials.gov
• MS Detection of Somatic Mutations in Hematological Malignancies#879488ClinicalTrials.gov
• Exploratory Study on in Vivo CAR-T Therapy Targeting CD20 for the Treatment of Hematological Malignancies#125824ClinicalTrials.gov
• COVID19-hematological Malignancies: the Italian Hematology Alliance#834692ClinicalTrials.gov
• Study of ABT-751 in Patients With Refractory Hematologic Malignancies#899636ClinicalTrials.gov
• Intrabone Cord Blood Transplantation#1072926ClinicalTrials.gov
• Observational Study for the Evaluation of Immune-mediated Endocrinological Adverse Events in Patients With Hematological Malignancies and Subjected to Treatment With Immune-checkpoint Inhibitors#474874ClinicalTrials.gov
• Characteristics and Outcomes of Patients With Hematological Malignancies#1322102ClinicalTrials.gov
• Correlation Between Gut Microbiota and Clinical Response to CAR-T Treatment for Hematological Malignancies#1047716ClinicalTrials.gov
• Haplo-PBSC+Cord vs Haplo-PBSC+BM for Hematological Malignancies Undergoing Allo-HSCT#1409065ClinicalTrials.gov
• Assess the Oral Bioavailability of New ABT-263 Formulations#880350ClinicalTrials.gov
• A Study to Determine the Absorption, Distribution, Metabolism, and Excretion of LBH589#1282877ClinicalTrials.gov
• Umbilical Cord Blood Transplant for Children With Myeloid Hematological Malignancies#1421622ClinicalTrials.gov